Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

429
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
429
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

805
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
805
Gastrointestinal Motility Disorders01:20

Gastrointestinal Motility Disorders

644
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
644
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

719
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
719
Neural Regulation01:37

Neural Regulation

40.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

906
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
906

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T<sub>1</sub>ρ Magnetic Resonance Fingerprinting in Patients With Chronic Pancreatitis.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease.

Journal of Parkinson's disease·2026
Same author

Digital Gait Measures Discriminate People with Friedreich's Ataxia from Healthy Controls.

Movement disorders clinical practice·2025
Same author

Thermoregulatory Dysfunction in Parkinson's Disease: Mechanisms, Implications, and Therapeutic Perspectives.

Cells·2025
Same author

Novel Interdisciplinary Gastroenterology and Parkinson's Disease Clinic in a Parkinson's Center of Excellence.

Movement disorders clinical practice·2025
Same author

Associations Between Cognitive Profiles and Balance in Essential Tremor.

Tremor and other hyperkinetic movements (New York, N.Y.)·2025

Related Experiment Video

Updated: Oct 5, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.0K

Gastrointestinal Dysfunction in Parkinson's Disease.

Delaram Safarpour1, Kaveh Sharzehi2, Ronald F Pfeiffer3

  • 1Department of Neurology, Oregon Health & Science University, Portland, OR, USA. safarpou@ohsu.edu.

Drugs
|January 25, 2022
PubMed
Summary
This summary is machine-generated.

Gastrointestinal dysfunction is common in Parkinson's disease (PD), with gut pathology potentially initiating disease spread. Understanding these changes is crucial for effective PD medication management.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.0K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K

Related Experiment Videos

Last Updated: Oct 5, 2025

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
03:20

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease

Published on: September 22, 2023

2.0K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.0K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.0K

Area of Science:

  • Neuroscience
  • Gastroenterology
  • Microbiology

Background:

  • Growing evidence links gastrointestinal (GI) dysfunction to Parkinson's disease (PD) over the last 30 years.
  • Pathology in the enteric nervous system (ENS) suggests the GI tract may be an origin or entry point for PD.
  • Gut microbiota dysbiosis is increasingly recognized in association with PD.

Purpose of the Study:

  • To review current knowledge on GI pathophysiology and microbiome changes in Parkinson's disease.
  • To explore how these GI changes evolve with disease progression.
  • To discuss common GI problems in PD, their diagnostic evaluations, and treatment options.

Main Methods:

  • Review of existing literature on Parkinson's disease, gastrointestinal dysfunction, and the gut microbiome.
  • Focus on clinical manifestations, pathophysiology, and therapeutic strategies.
  • Analysis of the relationship between GI changes and PD medication response.

Main Results:

  • Clinical features of GI dysfunction in PD are well-identified.
  • The GI tract and ENS are implicated in PD pathogenesis and pathology spread to the CNS via the vagus nerve.
  • Changes in the gut microbiome are associated with PD.

Conclusions:

  • GI dysfunction is a significant component of Parkinson's disease.
  • Understanding GI pathophysiology and microbiome alterations is vital for managing PD and its treatment responses.
  • Further research into GI-targeted diagnostics and therapeutics for PD is warranted.